ACST Stock – (NASDAQ: ACST) is actually giving an update on the use

ACST Stock – (NASDAQ: ACST) is providing an update on the use

ACST
-1.84%
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is giving an update on the use of the “at the market” equity of its offering plan.

As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Wainwright & Co., LLC (collectively, the “Agents”), to put into practice an “at-the market” equity offering program under which Acasti may issue and sell from time to time its common shares having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January twenty seven, 2021, Acasti issued an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares were marketed at prevailing market rates averaging US$1.0747 a share. No securities were sold through the facilities of the TSXV or perhaps, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July 7, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate yucky proceeds raised was given to the Agents in connection with the services of theirs. As a direct result of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and superb as of March 5, 2021.

The extra capital raised has strengthened Acasti’s balance sheet and often will supply the Company with supplemental flexibility in its ongoing review process to explore and evaluate strategic options.

About Acasti – ACST Stock

Acasti is actually a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescription medications making use of OM3 greasy acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical proof of safety as well as efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being formulated for people with severe HTG.

Forward Looking Statements – ACST Stock

Statements in that press release that aren’t statements of historical or current fact constitute “forward-looking information” to the meaning of Canadian securities laws and “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking statements include known and unknown risks, uncertainties, and other unknown variables that may result in the actual outcomes of Acasti to be materially different from historical outcomes and even from any later outcomes expressed or implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks and uncertainties, readers are actually urged to give some thought to statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other similar expressions to be uncertain and forward-looking. Readers are actually cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the date of this press release. Forward-looking statements in this press release include, but aren’t limited to, info or statements about Acasti’s strategy, succeeding operations and its review of strategic alternatives.

The forward looking assertions found in this press release are expressly qualified in the entirety of theirs by this alerting statement, the “Special Note Regarding Forward Looking Statements” area contained in Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com as well as on the investor area of Acasti’s website at www.acastipharma.com. All forward looking claims in that press release exist as of the day of this press release.

ACST Stock – Acasti does not undertake to redesign some such forward looking statements whether as a direct result of brand new information, future events or perhaps otherwise, except as required by law. The forward-looking assertions contained herein are also subject typically to assumptions and risks as well as uncertainties that are actually discussed from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use